Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

@article{Michels2009SunitinibIT,
  title={Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma},
  author={Judith Michels and Nathalie Lassau and Marine Gross-Goupil and Christophe C Massard and Arnaud M{\'e}jean and Bernard Escudier},
  journal={Investigational New Drugs},
  year={2009},
  volume={28},
  pages={690-693}
}
Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.